BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2021

View Archived Issues

Algernon repurposes a psychedelic drug as potential treatment for stroke

Read More

Akari announces development of its second clinical candidate, votucalis

Read More

New mouse model points to mitochondrial dynamics as key to neurodegeneration

Read More

BiomX reports first-in-human data with phage therapy candidate BX-002

Read More

Kira initiates first-in-human study of P-014 for complement-mediated diseases

Read More

FDA approves Posimir for post-surgical pain following arthroscopic subacromial decompression

Read More

CSL Behring initiates Australian study of CSL-760 to treat serious cases of COVID-19

Read More

Annamycin shows significant therapeutic benefit in metastatic osteosarcoma animal model

Read More

Cassava Sciences presents interim analysis data for simufilam in patients with Alzheimer's disease

Read More

University of Southern California and collaborators patent opioid receptor agonists

Read More

BioCardia announces pipeline updates and milestones

Read More

Phase I data presented for AXL inhibitor DS-1205c plus osimertinib in EGFR-mutated NSCLC

Read More

Curis initiates phase II LUCAS study of CA-4948 as treatment for anemia in MDS

Read More

DexTech expands preclinical program to evaluate OsteoDex in multiple myeloma

Read More

Tyvyt approved in China for first-line nonsquamous NSCLC

Read More

"Expansion sequencing" gives elbow room to in situ transcriptomics

Read More

Dual EGFR/LRG5 blockade with MCLA-158 shows promise in phase I study in metastatic CRC

Read More

Botanix reports data from phase IIa study of BTX-1801 for S. aureus nasal decolonization

Read More

UB-612 multitope peptide-based vaccine against COVID-19 enters phase II trials in Taiwan

Read More

Targeting ketohexokinase as new therapeutic strategy in NAFLD

Read More

Publication details phase III results with Gam-COVID-Vac (Sputnik V) vaccine

Read More

NSUN2 is a prognostic biomarker in NSCLC

Read More

Vaccitech begins phase Ib/IIa study of VTP-300 for chronic hepatitis B infection

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing